iRhythm Holdings, Inc. Research and Development Expense
iRhythm Holdings, Inc. (IRTC) reported Research and Development Expense of $19.69 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2024-08-01
- iRhythm Holdings, Inc. research and development expense for the quarter ending 2024-06-30 was $19.69M, a 43.96% increase year-over-year.
- iRhythm Holdings, Inc. research and development expense for the quarter ending 2024-03-31 was $16.99M, a 14.50% increase year-over-year.
- iRhythm Holdings, Inc. research and development expense for the quarter ending 2023-12-31 was $15.42M, a 21.63% increase year-over-year.
- iRhythm Holdings, Inc. research and development expense for the quarter ending 2023-09-30 was $16.31M, a 42.46% increase year-over-year.
- iRhythm Holdings, Inc. research and development expense for fiscal 2023 was $60.24M, a 29.25% increase from fiscal 2022.
- iRhythm Holdings, Inc. research and development expense for fiscal 2022 was $46.61M, a 20.53% increase from fiscal 2021.
- iRhythm Holdings, Inc. research and development expense for fiscal 2021 was $38.67M, a 6.43% decline from fiscal 2020.
- iRhythm Holdings, Inc. research and development expense for fiscal 2020 was $41.33M, a 10.80% increase from fiscal 2019.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | $19.69M 10-Q · filed 2024-08-01 | $36.68M 10-Q · filed 2024-08-01 | $52.10M derived: sum of 3 quarters · filed 2024-08-01 | $68.41M derived: sum of 4 quarters · filed 2024-08-01 | ||||
| 2024-03-31 | $16.99M 10-Q · filed 2024-05-02 | $32.41M derived: sum of 2 quarters · filed 2024-05-02 | $48.72M derived: sum of 3 quarters · filed 2024-05-02 | $62.40M derived: sum of 4 quarters · filed 2024-08-01 | ||||
| 2023-12-31 | $15.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $31.73M derived: sum of 2 quarters · filed 2024-02-22 | $45.40M derived: sum of 3 quarters · filed 2024-08-01 | $60.24M 10-K · filed 2024-02-22 | ||||
| 2023-09-30 | $16.31M 10-Q · filed 2023-11-02 | $29.99M derived: sum of 2 quarters · filed 2024-08-01 | $44.83M 10-Q · filed 2023-11-02 | $57.50M derived: sum of 4 quarters · filed 2024-08-01 | ||||
| 2023-06-30 | $13.68M 10-Q · filed 2024-08-01 | $28.52M 10-Q · filed 2024-08-01 | $41.19M derived: sum of 3 quarters · filed 2024-08-01 | $52.64M derived: sum of 4 quarters · filed 2024-08-01 | ||||
| 2023-03-31 | $14.84M 10-Q · filed 2024-05-02 | $27.52M derived: sum of 2 quarters · filed 2024-05-02 | $38.97M derived: sum of 3 quarters · filed 2024-05-02 | $50.91M derived: sum of 4 quarters · filed 2024-05-02 | ||||
| 2022-12-31 | $12.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $24.12M derived: sum of 2 quarters · filed 2024-02-22 | $36.07M derived: sum of 3 quarters · filed 2024-02-22 | $46.61M 10-K · filed 2024-02-22 | ||||
| 2022-09-30 | $11.45M 10-Q · filed 2023-11-02 | $23.39M derived: sum of 2 quarters · filed 2023-11-02 | $33.94M 10-Q · filed 2023-11-02 | $45.80M derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2022-06-30 | $11.95M 10-Q · filed 2023-08-04 | $22.49M 10-Q · filed 2023-08-04 | $34.36M derived: sum of 3 quarters · filed 2024-02-22 | $43.04M derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2022-03-31 | $10.54M 10-Q · filed 2023-05-04 | $22.41M derived: sum of 2 quarters · filed 2024-02-22 | $31.10M derived: sum of 3 quarters · filed 2024-02-22 | $40.70M derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2021-12-31 | $11.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $20.55M derived: sum of 2 quarters · filed 2024-02-22 | $30.16M derived: sum of 3 quarters · filed 2024-02-22 | $38.67M 10-K · filed 2024-02-22 | ||||
| 2021-09-30 | $8.69M 10-Q · filed 2022-11-04 | $18.29M derived: sum of 2 quarters · filed 2022-11-04 | $26.80M 10-Q · filed 2022-11-04 | $38.41M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-06-30 | $9.61M 10-Q · filed 2022-08-05 | $18.12M 10-Q · filed 2022-08-05 | $29.72M derived: sum of 3 quarters · filed 2023-02-23 | $38.49M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-03-31 | $8.51M 10-Q · filed 2022-05-06 | $20.11M derived: sum of 2 quarters · filed 2023-02-23 | $28.88M derived: sum of 3 quarters · filed 2023-02-23 | $41.42M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2020-12-31 | $11.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $20.37M derived: sum of 2 quarters · filed 2023-02-23 | $32.91M derived: sum of 3 quarters · filed 2023-02-23 | $41.33M 10-K · filed 2023-02-23 | ||||
| 2020-09-30 | $8.77M 10-Q · filed 2021-11-05 | $21.31M derived: sum of 2 quarters · filed 2021-11-05 | $29.73M 10-Q · filed 2021-11-05 | $38.99M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $12.54M 10-Q · filed 2021-08-09 | $20.96M 10-Q · filed 2021-08-09 | $30.23M derived: sum of 3 quarters · filed 2022-02-28 | $43.72M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $8.41M 10-Q · filed 2021-05-10 | $17.68M derived: sum of 2 quarters · filed 2022-02-28 | $31.18M derived: sum of 3 quarters · filed 2022-02-28 | $39.02M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $9.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $22.77M derived: sum of 2 quarters · filed 2022-02-28 | $30.60M derived: sum of 3 quarters · filed 2022-02-28 | $37.30M 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | $13.50M 10-Q · filed 2020-11-06 | $21.33M derived: sum of 2 quarters · filed 2020-11-06 | $28.03M 10-Q · filed 2020-11-06 | $35.12M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-06-30 | $7.83M 10-Q · filed 2020-08-07 | $8.64M 10-Q · filed 2019-08-06 | $14.53M 10-Q · filed 2020-08-07 | $15.39M 10-Q · filed 2019-08-06 | $21.62M derived: sum of 3 quarters · filed 2021-02-26 | $26.70M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2019-03-31 | $6.70M 10-Q · filed 2020-05-08 | $6.76M 10-Q · filed 2019-05-10 | $13.78M derived: sum of 2 quarters · filed 2021-02-26 | $18.87M derived: sum of 3 quarters · filed 2021-02-26 | $23.52M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2018-12-31 | $7.08M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $12.17M derived: sum of 2 quarters · filed 2021-02-26 | $16.82M derived: sum of 3 quarters · filed 2021-02-26 | $20.86M 10-K · filed 2021-02-26 | $20.75M 10-K · filed 2019-03-04 | |||
| 2018-09-30 | $5.09M 10-Q · filed 2019-12-23 | $5.16M 10-Q · filed 2018-10-30 | $9.73M derived: sum of 2 quarters · filed 2019-12-23 | $13.78M 10-Q · filed 2019-12-23 | $13.75M 10-Q · filed 2018-10-30 | $17.85M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-06-30 | $4.65M 10-Q · filed 2019-12-23 | $4.56M 10-Q · filed 2018-08-03 | $8.69M 10-Q · filed 2019-12-23 | $8.58M 10-Q · filed 2018-08-03 | $12.77M derived: sum of 3 quarters · filed 2020-03-02 | $16.56M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-03-31 | $4.04M 10-Q · filed 2019-12-23 | $4.02M 10-Q · filed 2018-05-10 | $8.12M derived: sum of 2 quarters · filed 2020-03-02 | $11.91M derived: sum of 3 quarters · filed 2020-03-02 | $14.69M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2017-12-31 | $4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $7.87M derived: sum of 2 quarters · filed 2020-03-02 | $10.64M derived: sum of 3 quarters · filed 2020-03-02 | $13.27M 10-K · filed 2020-03-02 | $13.34M 10-K · filed 2018-03-01 | |||
| 2017-09-30 | $3.79M 10-Q · filed 2018-10-30 | $6.57M derived: sum of 2 quarters · filed 2018-10-30 | $9.19M 10-Q · filed 2018-10-30 | $11.49M derived: sum of 4 quarters · filed 2019-03-04 | ||||
| 2017-06-30 | $2.78M 10-Q · filed 2018-08-03 | $5.40M 10-Q · filed 2018-08-03 | $7.70M derived: sum of 3 quarters · filed 2019-03-04 | $9.34M derived: sum of 4 quarters · filed 2019-03-04 | ||||
| 2017-03-31 | $2.62M 10-Q · filed 2018-05-10 | $4.92M derived: sum of 2 quarters · filed 2019-03-04 | $6.56M derived: sum of 3 quarters · filed 2019-03-04 | $8.23M derived: sum of 4 quarters · filed 2019-03-04 | ||||
| 2016-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-04 | $3.94M derived: sum of 2 quarters · filed 2019-03-04 | $5.61M derived: sum of 3 quarters · filed 2019-03-04 | $7.15M 10-K · filed 2019-03-04 | ||||
| 2016-09-30 | $1.64M 10-Q · filed 2017-11-14 | $3.30M derived: sum of 2 quarters · filed 2017-11-14 | $4.85M 10-Q · filed 2017-11-14 | $6.65M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-06-30 | $1.67M 10-Q · filed 2017-08-07 | $3.21M 10-Q · filed 2017-08-07 | $5.01M derived: sum of 3 quarters · filed 2018-03-01 | $6.66M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-03-31 | $1.54M 10-Q · filed 2017-05-12 | $3.35M derived: sum of 2 quarters · filed 2018-03-01 | $5.00M derived: sum of 3 quarters · filed 2018-03-01 | |||||
| 2015-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $3.45M derived: sum of 2 quarters · filed 2018-03-01 | $6.35M 10-K · filed 2018-03-01 | |||||
| 2015-09-30 | $1.65M 10-Q · filed 2016-12-05 | $4.55M 10-Q · filed 2016-12-05 | ||||||
| 2014-12-31 | $5.70M 10-K · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PULSE BIOSCIENCES, INC. (PLSE) | United States | $3.696B | -24.47 |
| ICU MEDICAL INC/DE (ICUI) | United States | $4.153B | 18.85 |
| AtriCure, Inc. (ATRC) | United States | $3.089B | |
| Heartflow, Inc. (HTFL) | United States | $4.225B | |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| NovoCure Ltd (NVCR) | $1.886B | -11.87 |